{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:30:50Z","timestamp":1786426250482,"version":"build-2736575974"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>Pancreatic amphicrine-like carcinoma (ALC) is an exceptionally rare neoplasm characterized by simultaneous exocrine and endocrine differentiation within the same tumour cells. These tumours represent a diagnostic challenge because they must be distinguished from mixed neuroendocrine\u2013non-neuroendocrine neoplasms (MiNENs), which consist of morphologically distinct tumour components. We report a case of pancreatic ALC with acinar differentiation harboring a KANK4::RAF1 fusion identified by comprehensive genomic profiling. Histologically, the tumour demonstrated acinar differentiation with expression of trypsin and BCL10 together with neuroendocrine differentiation characterized by synaptophysin and INSM1 expression within the same neoplastic population. Molecular analysis revealed a RAF1 rearrangement, a potentially actionable alteration previously described in a subset of pancreatic acinar carcinomas. The patient showed rapid disease progression despite systemic chemotherapy. Treatment with the MEK inhibitor trametinib was initiated based on the presence of a RAF1 fusion but was discontinued after 1\u00a0month because of toxicity, preventing assessment of therapeutic efficacy. This case expands the molecular spectrum of pancreatic ALC with acinar differentiation and highlights the importance of comprehensive molecular profiling in rare pancreatic neoplasms to identify potentially actionable genomic alterations.<\/jats:p>","DOI":"10.3389\/pore.2026.1612537","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:10:12Z","timestamp":1786425012000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Pancreatic amphicrine-like carcinoma with acinar differentiation harboring a KANK4-RAF1 gene fusion"],"prefix":"10.3389","volume":"32","author":[{"given":"Sabrina","family":"Kammerer","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology","place":["Kantonsspital Winterthur, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bode","sequence":"additional","affiliation":[{"name":"Department of Pathology","place":["Kantonsspital Winterthur, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heide","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Pathology","place":["Kantonsspital Winterthur, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guacimara","family":"Ortega Sanchez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology","place":["Kantonsspital Winterthur, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/biomedicines5040065","article-title":"Pancreatic cancer: molecular characterization, clonal evolution and cancer stem cells","volume":"5","author":"Pelosi","year":"2017","journal-title":"Biomedicines"},{"key":"B2","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleef","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2174\/1389200218666170201151135","article-title":"Pancreatic cancer therapy review: from classic therapeutic agents to modern nanotechnologies","volume":"18","author":"Rebelo","year":"2017","journal-title":"Curr Drug Met"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.3748\/wjg.v28.i40.5827","article-title":"Pancreatic acinar cell carcinoma: a comprehensive review","volume":"28","author":"Calimano-Ramirez","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B5","article-title":"Pancreatic neuroendocrine tumors","volume-title":"StatPearls","author":"Helbing","year":"2026"},{"key":"B6","volume-title":"Digestive Tumours","year":"2026"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/s41379-020-0545-9","article-title":"RAF1 rearrangements are common in pancreatic acinar cell carcinomas","volume":"33","author":"Prall","year":"2020","journal-title":"Mod Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00159","article-title":"MEK inhibitor therapy in carcinomas with RAF1 fusions: inferior response in a patient with pancreatic acinar cell carcinoma","volume":"3","author":"McEvoy","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"105903","DOI":"10.1016\/j.biocel.2020.105903","article-title":"KANK family proteins in cancer","volume":"131","author":"Tadijan","year":"2021","journal-title":"Int J Biochem Cell Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.18632\/oncotarget.28403","article-title":"A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850","volume":"14","author":"Spencer","year":"2023","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00494","article-title":"Retrospective case series analysis of RAF family alterations in pancreatic cancer: real-world outcomes from targeted and standard therapies","volume":"5","author":"Hendifar","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e193205","DOI":"10.1172\/JCI193205","article-title":"Switching on the evolutionary potential of pancreatic cancer: the tumor suppressor functions of PBRM1","volume":"135","author":"Perelli","year":"2025","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s43018-025-01047-5","article-title":"SMAD4 induces opposite effects on metastatic growth from pancreatic tumors depending on the organ of residence","volume":"6","author":"Tsanov","year":"2025","journal-title":"Nat Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.4049\/jimmunol.1900475","article-title":"Frequent loss of IRF2 in cancers leads to immune evasion through decreased MHC class I antigen presentation and increased PD-L1 expression","volume":"203","author":"Kriegsman","year":"2019","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e70094","DOI":"10.1111\/pin.70094","article-title":"Pancreatic amphicrine carcinoma with acinar and neuroendocrine differentiation: a comprehensive case with radiological, cytopathological and ultrastructural findings, and literature review","volume":"76","author":"Hashimoto","year":"2026","journal-title":"Pathol Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s12022-016-9432-9","article-title":"Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs): unifying the concept of a heterogeneous group of neoplasms","volume":"27","author":"La","year":"2016","journal-title":"Endocr Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/jcm9010273","article-title":"Mixed neuroendocrine non-neuroendocrine neoplasms: a systematic review of a controversial and underestimated diagnosis","volume":"9","author":"Frizziero","year":"2020","journal-title":"J Clin Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s12022-020-09628-z","article-title":"Morphologic variants of pancreatic neuroendocrine tumors: clinicopathologic analysis and prognostic stratification","volume":"31","author":"Xue","year":"2020","journal-title":"Endocr Pathol"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.55418\/9781933477275","volume-title":"Tumors of the Pancreas","author":"Klimstra","year":"2023"}],"container-title":["Pathology &amp; Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2026.1612537\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:10:14Z","timestamp":1786425014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2026.1612537\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":19,"alternative-id":["10.3389\/pore.2026.1612537"],"URL":"https:\/\/doi.org\/10.3389\/pore.2026.1612537","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1612537"}}